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Background: Many patients with chronic obstructive pulmonary disease (COPD) experi-
ence exacerbations of symptoms, leading to a large burden on patients and the health system 
and costs to society. To address this burden, a 25% reduction in number of hospitalization 
days for COPD exacerbations was recently declared a national goal in the Netherlands, to be 
achieved in 5 years.
Methods: A national care pathway was designed following an established managed clinical 
pathway setup, which involved prior national surveys and the identification of ten key 
elements. The concept was discussed, made locally applicable, and finally tested in eight 
regions containing eleven hospitals and surrounding primary-care groups in a prospective 
cohort study. All patients were followed for 1 year, starting at hospitalization.
Results: In total, 752 patients gave informed consent and participated (mean age 70 years, 
58% female). Of these, 120 (16%) died within a year. The median length of index hospita-
lization was 5 days, and 43% had at least one rehospitalization within 1 year (range 0–8). 
There was a 19.4% reduction in number of total hospitalization days, without a decrease in 
health-related quality of life or perceived quality of care. Elements that contributed signifi-
cantly to the reduction were contact in the first week after hospitalization, and during the year 
of follow-up pharmacological and nonpharmacological smoking-cessation guidance, checks 
on inhalation technique, and discussion of lung-attack plan.
Discussion: With concerted action between patients and health workers in the hospital and 
in the community, a large reduction in number of hospitalization days can be achieved. The 
program was quite demanding for both patients and health workers. In our subsequent 
national implementation plan after this pilot study, we have named the major contributors 
to success and advocate the stepwise introduction of the elements in light of feasibility.
Keywords: COPD, National Action Program, managed-care pathway, hospitalization
Introduction
Many patients with chronic obstructive pulmonary disease (COPD) experience 
exacerbations of symptoms.1 Frequent exacerbations are associated with lower 
quality of life and faster decline in lung function.2–4 Between 3% and 20% of 
patients require at least one hospital admission per year, and mortality rates after 
admission are very high, up to 43% after 2 years.2,5–8 The economic burden of 
COPD is thus substantial. In the Netherlands, it is estimated that hospitalizations 
account for 33%–57% of total costs of COPD, depending on the survey method.9,10 
In many countries, this percentage is even higher, up to 84%.5 This economic 
burden is becoming increasingly difficult to bear. As an additional worry, the 
number of patients with COPD will increase in coming years, mainly because of 
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aging of the population and past smoking, thereby adding 
to the challenges of appropriate care.
With the aim of improving the level of care in the 
Netherlands while curbing the costs and burden to patients 
and society, the Lung Alliance Netherlands (LAN) started 
a National Action Program for Chronic Lung Diseases 
with five SMART (specific, measurable, achievable, rea-
listic, and timely) goals. The first of these goals was to 
reduce the number of days hospitalized because of 
obstructive-airway diseases by 25% in 5 years.11,12 To 
reach this goal, a managed-care pathway for COPD was 
designed. We defined the goal as the reduction in hospita-
lization days plus at least maintaining health-related qual-
ity of care and patient perception of quality of care. In this 
paper, we describe the design of the care pathway, the 
results of the pilot study assessing which interventions 
were successful, and discuss recommendations for nation-
wide implementation of the care pathway.
Methods
Care-Pathway Design
To design, implement and evaluate the care pathway, the 
seven-phase method of the European Pathway Association 
was used.13 The seven phases are screening, project man-
agement, assessment of current situation, care-pathway 
development, implementation, evaluation, and continuous 
follow up. Given the reach of the overriding national goal 
— 25% reduction in hospitalization days in 5 years — it 
was clear that a transmural endeavor was needed, ie, with 
equal participation from in-hospital and community-based 
experts. Care was taken to ensure patient participation via 
the Dutch Lung Foundation, next to pulmonary physicians, 
general practitioners, nurses, psychologists, dieticians, 
physiotherapists, pharmacists, and managed care–pathway 
specialists. The aforementioned participants for defining 
the content of the care pathway were recruited by formal 
invitation as delegates from their respective professional 
societies or via the Lung Foundation for patients.
Assessment of Current Situation
The current situation, phase 3, was assessed nationwide 
and locally with patients and health-care providers. 
Nationally, in close collaboration with the Dutch Lung 
Foundation, two patient focus groups were recruited from 
members of their patient panel and interviewed. Also 
nationally, all pulmonary physicians and GPs were sur-
veyed on the organization of care in their hospital or GP’s 
office, and on bottlenecks for better care. Via the public 
website of the Dutch Lung Alliance, some specifically 
involved other health-care providers such as respiratory 
nurses and physiotherapists, also responded to the survey.
All hospital regions (ie, hospitals with surrounding 
GP practices) in the Netherlands were invited to parti-
cipate in making and piloting the COPD-care pathway. 
Of 92 regions, 33 responded, of which eight regions, 
comprising eleven hospitals, were selected, based on 
equal spread in geographic region and setting (aca-
demic, large teaching, local hospital). At the start of 
the study in the participating regions, patient health- 
related quality of life and perceived quality of care 
were assessed in a standardized manner by the Clinical 
COPD Questionnaire (CCQ),14 Consumer Quality Index 
(CQI) — hospitalizations, CQI — asthma and 
COPD.15,16 These questionnaires were repeated toward 
the end of the study. The same questions were asked to 
patients in six control regions that had expressed interest 
in participating, but were not selected (again based on 
geographic spread). Hospitalization rates and lengths of 
COPD hospitalizations in the study regions were 
assessed where possible in 2013 and again in 2018.
Defining the Pathway
In phase 4, the start of the pathway was defined by hospi-
talization, and patients were to be followed for 1 year each 
primarily to document number of hospitalization days and 
other health-care utilization and to determine factors asso-
ciated with fewer hospitalization days over a year. The 
pathway described here was first conceived in an iterative 
process in dedicated meetings by national delegates from 
the aforementioned caregiver groups and patients to reach 
consensus on elements deemed most pivotal for a success-
ful transmural pathway. To guide these decisions, the base-
line data from phase 3 were used, and literature searches 
(unsystematic) were performed for successful interven-
tions documenting reductions in hospitalization days. The 
literature base found at the time was small and consisted 
mainly of pharmacological treatments in the hospital. Few 
evidence-based nonpharmacological interventions in and 
outside of the hospital were found. In our consensus meet-
ings, however, we estimated that the largest additionally 
achievable gains were to be nonpharmacological. The 
following ten elements were selected to be part of the 
care pathway.
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● Integral health status, to be screened on day 2 of the 
hospitalization, and with full assessment of coping and 
adaptation to be planned outside the hospital, including 
follow-up on items identified. Screening for anxiety 
and depression was also performed. We prioritized 
already on day 2 the evaluation of factors contributing 
to the hospitalization, expectations of the hospitaliza-
tion by caregivers and the patient, and identifiable 
factors likely to contribute to successful discharge.
● Individual care plan/lung attack (exacerbation) action 
plan, to be discussed with patients and their loved 
ones, starting during hospitalization and iteratively at 
home, including updates.
● Advance care planning/palliative care. The fact that 
hospitalization for a COPD exacerbation is associated 
with mortality of up to 43% in 2 years was deemed a 
sufficient reason for starting these discussions without 
need of further identification of patients at even further 
increased risk of shortened survival.6–8
● Medication and therapy compliance, with special focus 
on inhalation technique, repeated assessments while on 
the hospital ward, and again after discharge. 
Additionally, encourage as much as possible the use 
of the same inhalation medication and device as at 
home to practice and gain confidence in home 
medication.
● Smoking cessation through motivational techniques 
and pharmacological treatment, again starting on the 
ward and continued during the year at home.
● Mobility and exercise, early guidance by a phy-
siotherapist for all patients on the ward, and where 
necessary at home. Formal rehabilitation was offered 
for after discharge.
● Nutritional status assessment at hospitalization, and 
action taken as needed in or with outreach to outside 
the hospital.
● Comorbidity, broad alertness, and treatment as 
necessary.
● Other care according to guidelines (mostly pharma-
cological). A national multidisciplinary guideline, 
specifically aimed at the treatment of COPD exacer-
bations in the hospital, was made in parallel to the 
development of this care pathway.
● Monitoring and logistics: assessments of quality of 
life, dedicated planning of consultations with patients 
and loved ones. The first of these consultations after 
discharge was planned within a week to prevent early 
relapse and was coordinated by a case manager.
In our care pathway, we were careful to describe what 
needed to be done or provided, not who should do it. It 
was for the different regions to decide what was feasible 
for whom.
Patients and Centers
The care pathway described was subsequently tested in 
eight pilot regions (start of phase 5), consisting of eleven 
participating hospitals (12% of all Dutch hospitals) and 
associated regional primary-care groups. The regions were 
guided in translating the ten elements into practical, local 
protocols, including documenting who was responsible for 
what part of the managed-care pathway. Toolboxes were 
created centrally to facilitate implementation. In each 
region, the first 100 patients admitted for an exacerbation 
of COPD for the first time since the start of the study were 
recruited. This was labeled the index hospitalization. All 
additional hospitalizations for COPD within 1-year follow- 
up per individual were also treated as per the pathway. 
Since care was deemed to be optimal care and no interven-
tions were experimental, the study had the need for formal 
approval waived by the Medical Ethics Committee of 
Groningen. However, central data collection using a web- 
based online database, OpenClinica, was done only with 
written informed consent.
Statistical Analyses
Starting at the initial hospitalization, a trajectory of 1 year 
per patient was started, during which data were collected 
during admission, and when applicable readmissions, as 
well as during other planned and unplanned visits to all 
other health-care providers, especially GPs. In this low- 
budget cohort study, we encountered missing data because 
of mortality and other reasons. Where pivotal questions 
documenting whether specific interventions had been per-
formed were not completed, the items were conservatively 
classified as “not performed”.
In the statistical part of our implementation study, we 
were above all interested in which interventions from our 
extensive program were associated with fewer hospitaliza-
tion days. To account for variable follow-up, hospitaliza-
tion days were censored at 1 year and recalculated as 
percentage of the period hospitalized in further statistical 
analyses. The natural logarithm of this percentage was 
used in analyses to normalize the distribution and allow 
for linear regression. We anticipated a few baseline char-
acteristics, especially age, GOLD stage, and smoking sta-
tus, to be related to hospitalizations and checked these 
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factors first (Table 3). Subsequently, multiple linear regres-
sion, corrected for significant baseline characteristics and 
follow-up length, was used to analyze correlations 
between interventions and the percentage of period hospi-
talized. The threshold for statistical significance was 
P≤0.05. All statistical tests were performed using IBM 
SPSS software.
Results
From January 2015 to August 2018, 752 patients were 
managed in the care pathway and provided written 
informed consent to be included in the analyses. The base-
line characteristics of the study group are depicted in 
Table 1. Over the 1-year follow-up per patient, 120 
patients died (16%), and 12 additional patients were lost 
to follow-up for different reasons (Table 2). The median 
follow-up was 365 days as expected. The median percen-
tage of time hospitalized was 2.74% (range 0.3 - 91%). 
Number of days hospitalized and number of hospitaliza-
tions during the 1-year follow-up are depicted in Figures 1 
and 2, respectively. As expected, the percentage of period 
hospitalized was significantly greater with lower FEV1 
percentage predicted, oxygen supplementation at home, 
prednisolone or antibiotic maintenance treatment, and 
more prior COPD exacerbations or hospital admissions 
due to COPD exacerbation (Table 3), and thus these para-
meters were entered as covariates in the final analyses.
Interventions
Interventions significantly correlated with less hospitaliza-
tion were contact in the first week after discharge from the 
hospital, starting nonpharmacological or pharmacological 
smoking-cessation guidance later during the year (ana-
lyzed only in the smoker group), reviewing the patient’s 
lung-attack action plan later during the year, and checking 
the medication-inhalation technique later during the year 
(Table 4). To our surprise, checking the medication-inhala-
tion technique during hospitalization was negatively cor-
related with the percentage of period hospitalized.
Regional Differences
There was considerable variability among the regions in 
implementation of the different interventions. As an exam-
ple, Figure 3 shows the variability in contact between 
caregiver and patient in the first week after discharge 
from the hospital, and the percentage of those contacts 
that were actually home visits.
Overall COPD Hospitalization Data
In five of the eight participating regions, it was possible to 
collect regional data on overall number of hospitalization 
days in 2013, ie, before the start of this managed-care 
pathway, and in 2018 (Figure 4). In four of these five 
regions, overall admission days and percentage of read-
missions were reduced during the pilot year in comparison 
to 2013, amounting to an overall reduction of 19.4%.
Health-Related Quality of Life and 
Patient-Perceived Quality of Care
CCQ data were collected from 590 patients in 2013 and 
401 in 2018, independently of the interventional study. 
Table 1 Baseline Characteristics (n=752)
Age, years (mean ± SD) 69.6±10.0
Female (%) 58.2
BMI, median (range) 24.0 (11.4–52.6)
Current smoker (%) 38.2
Number of comorbidities, median (range) 1.0 (0–7)
Congestive heart failure (%) 7.3
Respiratory medication (%) Only LABA 2.8
Only LAMA 5.7
LABA + ICS 21.8
LAMA + ICS 2.1
LABA + LAMA 11




Prednisolone maintenance treatment (%) 13.0
Antibiotic maintenance treatment (%) 10.6
Prednisolone in last 4 weeks (%) 46.0
Oxygen supplementation at home (%) 16.8
FEV1 % predicted (mean ± SD) 47.0±18.7




Hospital admissions due to 












Abbreviations: BMI, body-mass index; LABA, long-acting β2-agonist; LAMA, long- 
acting muscarinic antagonist; ICS, inhaled corticosteroid; FEV1, forced expiratory 
volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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CCQ scores deteriorated marginally in the study regions 
(2.86 in 2013 to 3.02 in 2018), as well as in the control 
regions (2.87 to 2.89). The changes found were not 
clinically significant (minimal clinically important dif-
ference 0.4) or statistically significantly different from 
each other. Patient-perceived quality of care regarding 
hospitalization for COPD and COPD care in general 
were assessed by the respective CQIs: the CQI for 
COPD hospitalization improved slightly in both the 
study regions and the control regions (by 0.07 and 
0.02 respectively), a small difference of 0.05 in favor 
of the study regions not being significant. Similarly, the 
perceived quality of care for COPD in general showed a 
small difference of 0.06 in favor of the study regions. 
Minimal clinically important differences have not been 
provided for either scale.
Discussion
Our managed-care pathway combined in the primary and 
secondary care setting led to fewer hospitalization days 
over 1 year of follow-up, without compromising quality of 
life or perceived quality of care. We believe this is an impor-
tant outcome, since exacerbations in general and undoubt-
edly those leading to hospitalizations impact patient quality 
of life and well-being, while also being responsible for 
approximately half of all costs for COPD. Any successful 
strategy to curb the number of days in hospital should be 
greeted with enthusiasm, especially when numbers of 
Table 2 Main Follow-Up Data
n
Died 120 (16%)
Other reasons for incomplete follow-up Moving away 1
Stopped participation 3
Other 8
Mean ± SD Median Range
Number of hospital admissions (including index) 1.8±1.2 1 1–8
Patients with at least one readmission (%) 43
Follow-up (days) 307.2±107.6 365 2–365
Percentage of period hospitalized 6.2±11.5 2.7 0.3–90.9
Length of stay of index hospitalization 6.9±5.5 5 0–55
Table 3 Correlations of Baseline Characteristics with Percentage of Period Hospitalized
β 95% CI P–Value
Lower Upper
Sex −0.095 −0.219 0.030 0.14
Age, years 0.003 −0.003 0.009 0.33
FEV1 % predicted −0.007 −0.01 −0.003 0.00*
Smoking status Ex-smoker 0.021 −0.274 0.316 0.89
Current smoker −0.092 −0.394 0.209 0.55
Unknown −0.266 −0.624 0.093 0.15
Inhaled corticosteroids −0.038 −0.170 0.095 0.58
Oxygen supplementation at home 0.315 0.153 0.477 0.00*
Prednisolone maintenance treatment 0.246 0.067 0.426 0.01*
Antibiotic maintenance treatment 0.241 0.045 0.438 0.02*
Number of COPD exacerbations in prior year 0.084 0.039 0.129 0.00*
Number of hospital admissions due to COPD exacerbation in prior year 0.191 0.128 0.253 0.00*
Notes: *P<0.05. β is the standardized regression coefficient
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patients with COPD are still on the rise, due to aging of the 
population and (past) smoking behavior.
The overall first goal of our National Action Program 
for Chronic Lung Diseases is a 25% reduction in number 
of days hospitalized because of COPD in 5 years.12 In our 
cohort study, we followed all patients for just 1 year. When 
comparing data from the same regions before and at the 
end of our study (2013–2018), we found an overall reduc-
tion of 19.4%, which is considerable. Five elements con-
tributed significantly to fewer hospitalization days: contact 
in first week after hospitalization and pharmacological and 
nonpharmacological smoking-cessation guidance, check-
ing inhalation technique, and discussion of lung-attack 
plan during the year of follow-up.





















Figure 1 Number of days hospitalized in 1 year (including index hospitalization).























Figure 2 Number of hospitalizations in 1 year (including index hospitalization).
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A significant and important contribution was patient 
contact in the first week after discharge (though in some 
cases, actually in the first 2 weeks). Given the generally 
high readmission rates in the first days after discharge,17 
this should make sense, but studies so far have been mixed 
in documenting the contribution of early contact to read-
mission rates.18,19 In this pilot, checks were not only on 
whether all instructions and medication schemes were well 
understood and sustainable but also on anxiety and social 
coping. Due to regional and sometimes logistic differ-
ences, some contacts were performed as home visits, 
whereas others were GP or outpatient visits or telephone 
contact only. We had anticipated that home visits would 
ultimately lead to the best results, and this was also corro-
borated by impressions of the health workers involved, but 
we were unable to demonstrate this. Our result could also 
be compatible with a (justified) selection in who was to be 
visited at home and who not. We were insufficiently 
informed on this latter selection aspect.
In line with the value of this early contact after dis-
charge was the value of repeated discussion of the lung- 
attack action plan. Self-management plans in general have 
been proven to improve care in COPD.20–22 In the 
Netherlands, we attempt not to use the general medical 
term “exacerbation” and have reframed this to use the 
phrase “lung attack” to facilitate communication with 
patients and their beloved.23 It also serves to stress to 
both patients and caregivers that 2-year mortality after a 
lung attack (COPD) is higher than after a heart attack. The 
central part of this lung-attack plan is what to do in cases 
of a (starting) attack and whom to contact, without making 
it too complex.
Checking inhalation technique repeatedly throughout 
the 1-year follow-up was associated with fewer hospitali-
zation days. This repeated check is so often advocated, but 
difficult to implement. Actually, in the current literature 
there is not a large body of evidence really demonstrating 
that it works.20,24 Similarly, coaching patients on stopping 
smoking and providing them with pharmacological help 
repeatedly during the year was also associated with fewer 
hospitalization days.25 Another contribution we believe to 
be important was the so-called day 2 meeting in the 
hospital with caregivers, patient, and family. This meeting 
had three goals: to understand what contributed to hospi-
talization, exchange expectations regarding hospitaliza-
tion, and anticipate on preparations needed for successful 




95% CI P-value 
(corrected)#
No& Yes No& Yes Lower Upper
Contact in first week after discharge 336 416 3.29 2.43 −0.293 −0.008 0.04*
Home visit as contact in first week 189 227 2.42 2.43 −0.119 0.244 0.50
Home visit later during the year 576 176 2.51 3.01 −0.043 0.276 0.15
Starting nonpharmacological smoking-cessation guidance during 
hospitalization for smokers
216 49 2.51 2.07 −0.233 0.337 0.72
Starting nonpharmacological smoking-cessation guidance later during year 
for smokers
243 22 2.53 1.37 −0.825 −0.075 0.02*
Starting pharmacological smoking-cessation guidance during hospitalization 
for smokers
219 46 2.19 2.74 −0.182 0.367 0.51
Starting pharmacological smoking-cessation guidance later during year for 
smokers
253 12 2.49 1.40 −1.074 −0.050 0.03*
Lung-attack action plan reviewed during hospitalization 316 436 2.27 3.28 −0.110 0.175 0.66
Lung-attack action plan reviewed later during year 473 279 3.29 2.19 −0.293 −0.010 0.04*
Inhalation technique checked during hospitalization 222 530 2.19 3.01 0.042 0.351 0.01*
Inhalation technique checked later during year 433 319 3.56 2.19 −0.328 −0.043 0.01*
Expectations of patient/family discussed during hospitalization 558 194 2.74 2.47 −0.121 0.194 0.65
Palliative care, care plans discussed during hospitalization 576 176 2.56 3.01 −0.029 0.303 0.11
Palliative care, care plans discussed later during year 689 63 2.74 2.73 −0.225 0.226 1.00
Day 2 meeting conducted 293 459 3.29 2.43 −0.276 0.008 0.06
Notes: &No or unknown; *P<0.05; #P-values from linear regression model corrected for significant baseline variables (Table 3) and length of follow-up.
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return home. We noticed that routine history-taking at the 
moment of hospitalization, frequently done by a junior 
doctor in the evening or at night, is focused on causal 
factors, such as infections, lack of medication compliance, 
and comorbidities. Asking patients on day 2 what contrib-
uted to the hospitalization, apart from the dyspnea they 
always have, led to the identification of quite different 
factors, such as reduced social support, anxiety, and 
depression. Making an early inventory of expectations of 
patients and their loved ones proved very useful. 
Conveying to patients on day 2 that the expected day of 



















Figure 3 Variability in patient contact per region in the first week after discharge. Dark blue bars represent percentage of patients contacted in the first week after 




























Figure 4 Overall change in COPD-admission days and COPD=readmission numbers between 2013 and 2018 per region and total. Dark blue bars represent percentage 
change in admission days; light blue percentage change in readmissions.
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it is not expected that all will be back to normal, but 
indeed that a patient will be better off at home than in 
the hospital. The third point on arrangements to be made 
for successful return home actually identifies factors that 
should not be postponed to the last day when checking the 
discharge bundle.
We were surprised to see that many interventions dur-
ing hospitalization could not be positively associated with 
any reduction in hospitalization days (already starting in 
the hospital: smoking-cessation counseling, both nonphar-
macological and pharmacological, discussing the lung- 
attack action plan, and starting palliative-care discussions) 
or were even negatively associated (medication-inhalation 
check during hospitalization). A possible contribution to 
these unexpected outcomes is the fact that the program 
was quite loaded in the median 5 days of hospitalization. 
Consequently, more of the care and discussions should 
perhaps be inventoried only while the patient is still in 
hospital, but further discussed when more stable after 
discharge.
During the pilot study, we learned that we started off 
too ambitiously. The feedback from the participating 
health-care workers and from patients expressed that 
there were too many elements implemented in a short 
time in the hospital. In our new version of the care path-
way, which is to be implemented nationwide, we have 
condensed the pathway to nine elements, and advocate 
starting with the three elements deemed most rewarding 
in the local context.26
Several other more general factors contributed to the 
overall favorable outcome. Above all, we believe the sense 
of urgency mattered: care just needs to improve, for many 
reasons.
Our setup was also important. This was a collaboration 
among hospital-based health workers, community health 
workers, and patients, united in the Lung Alliance 
Netherlands. The (limited) funding was in part from the 
Dutch Ministry of Health and the Innovation Fund of 
Dutch Insurers, but without any involvement with the 
content. While recruiting hospitals and associated pri-
mary-care groups, we were overwhelmed with a third of 
Dutch hospitals wanting to participate while being offered 
only start-up money. We could only accommodate eleven 
of the 33 hospital regions within our project. We believe 
that this signifies that there is a sense of urgency on the 
side of many caregivers inside and outside the hospital, as 
well as with patients who were actively involved.
The seven-phase method of the European Pathway 
Association described by Vanhaecht et al, a well-documen-
ted method, was utilized first at the national level for the 
general content, and thereafter within each participating 
hospital region.13 The latter allowed for a range of tailor- 
made solutions with major local ownership when deciding 
how to implement key interventions and assess feasibility, 
and for exchange of these solutions among regions. As an 
example, the mentioned contact in the first week after 
discharge differed considerably between regions, any-
where from phoning the patient by a hospital-based nurse 
to home visits by a community home-care service.
The median number of hospitalization days we found 
compares favorably not only to control regions in the 
Netherlands but also to 2016 data from Belgium, Italy, 
and Portugal in a cluster-randomized trial.27 Actually, the 
median number of days per hospitalization was 12 in their 
study and five in ours. An important difference in design 
was the fact that the latter study was hospital-based only, 
as opposed to ours. Lively discussions and dedicated con-
tact moments between caregivers inside and outside hos-
pital were indeed fruitful, although it remains a challenge 
to involve GPs, given that an average GP has only a few 
patients with repeated hospitalizations under his or her 
care, accounting for sometimes greater involvement of 
pulmonologists in our endeavor than GPs. Importantly, 
our day 2 meeting and contact in the first week after 
discharge were different from their study.
Our study also has some important shortcomings. First 
of all, the process of reaching consensus on the ten key 
elements where biggest gains were expected was not for-
malized, eg, in a Delphi-type process,28 but the results of 
piloting these in practice are described in this manuscript. 
Second, this was a cohort study, instead of a randomized 
controlled trial, though we did have control regions for 
two major outcome variables. Also, no formal power cal-
culation was made. Third, we had a considerable amount 
of missing data that we handled in a conservative way: 
when we were unsure whether a certain intervention was 
really provided to a patient, it was imputed as not given. 
Fourth, one region had a considerable relative increase in 
percentage of hospital days, from median 5 days to 6. This 
region had implemented the home-care visits just before 
the start of our national pathway and had the lowest 
median number of hospitalization days in 2013. 
Additionally, they faced a merger of two hospitals during 
the study period. The increase they encountered underlines 
how difficult it is to maintain intensive dedicated care. 
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Finally, it is prudent to consider a risk of bias while 
recruiting patients: we believe this to be limited, since 
we included the first 100 patients hospitalized for COPD 
per region with virtually no extra criteria, provided that 
they sufficiently mastered the Dutch language to be able to 
complete questionnaires.
In conclusion, with enthusiasm from within caregivers’ 
groups and a sense of urgency, though even without large 
sums of money, we were able to reduce the number of 
hospitalization days considerably. Contact within 1 week 
of discharge proved important, and a dedicated meeting on 
day 2 was deemed very valuable as well. We also learned 
not to include too many elements at the same time when 
changing care during an increasingly short hospital stay. 
Some interventions are better pinpointed and prepared 
during hospitalization, but organized and implemented 
shortly after hospitalization. Finally, maintaining the 
enthusiasm and thus the effects found will be one of the 
next challenges. We are now spreading the pathway over 
more regions in the Netherlands, with pilot regions from 
this study in the role of ambassadors. Dedicated patient 
versions of the care pathway have been made, including 
video materials for explanations of exacerbations and of 
elements of high-quality care.
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